Barclays Issues Positive Forecast for Humana (NYSE:HUM) Stock Price

Humana (NYSE:HUM - Get Free Report) had its price objective raised by analysts at Barclays from $255.00 to $270.00 in a note issued to investors on Thursday,Benzinga reports. The brokerage currently has an "equal weight" rating on the insurance provider's stock. Barclays's price objective would indicate a potential upside of 6.46% from the stock's current price.

Several other research analysts have also issued reports on the stock. Piper Sandler raised their price target on shares of Humana from $270.00 to $288.00 and gave the stock a "neutral" rating in a report on Wednesday, January 15th. Royal Bank of Canada restated an "outperform" rating and set a $283.00 price target on shares of Humana in a report on Wednesday, February 12th. Bank of America upgraded shares of Humana from an "underperform" rating to a "neutral" rating and raised their price target for the stock from $247.00 to $308.00 in a report on Wednesday, November 6th. Truist Financial raised their price target on shares of Humana from $260.00 to $290.00 and gave the stock a "hold" rating in a report on Monday, January 6th. Finally, Cantor Fitzgerald restated a "neutral" rating and set a $290.00 price target on shares of Humana in a report on Wednesday, February 12th. Nineteen analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, Humana has a consensus rating of "Hold" and a consensus target price of $293.05.

Humana Trading Up 0.3 %

NYSE:HUM traded up $0.73 during mid-day trading on Thursday, hitting $253.61. 2,386,047 shares of the company's stock were exchanged, compared to its average volume of 1,515,752. The company has a 50 day simple moving average of $271.27 and a 200-day simple moving average of $292.96. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.67. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $406.46. The firm has a market capitalization of $30.54 billion, a P/E ratio of 22.46, a PEG ratio of 2.11 and a beta of 0.56.

Humana (NYSE:HUM - Get Free Report) last posted its earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping the consensus estimate of ($2.26) by $0.10. Humana had a net margin of 1.18% and a return on equity of 13.20%. As a group, research analysts expect that Humana will post 16.11 earnings per share for the current year.

Insider Activity at Humana

In other Humana news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total transaction of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company's stock, valued at $2,096,463.06. The trade was a 31.16 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.32% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Humana

A number of hedge funds have recently bought and sold shares of the company. Mufg Securities Americas Inc. purchased a new position in Humana during the 4th quarter worth $451,000. Nissay Asset Management Corp Japan ADV boosted its holdings in Humana by 0.7% during the 4th quarter. Nissay Asset Management Corp Japan ADV now owns 14,792 shares of the insurance provider's stock worth $3,781,000 after acquiring an additional 107 shares during the last quarter. NorthRock Partners LLC boosted its holdings in Humana by 45.6% during the 4th quarter. NorthRock Partners LLC now owns 980 shares of the insurance provider's stock worth $249,000 after acquiring an additional 307 shares during the last quarter. Numerai GP LLC boosted its holdings in shares of Humana by 40.5% in the 4th quarter. Numerai GP LLC now owns 7,145 shares of the insurance provider's stock worth $1,813,000 after buying an additional 2,059 shares during the last quarter. Finally, OMERS ADMINISTRATION Corp boosted its holdings in shares of Humana by 2.4% in the 4th quarter. OMERS ADMINISTRATION Corp now owns 35,893 shares of the insurance provider's stock worth $9,106,000 after buying an additional 854 shares during the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.